NASDAQ:KMPH
Delisted
KemPharm Stock News
$5.81
+0 (+0%)
At Close: May 26, 2023
Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results
07:30am, Monday, 27'th Feb 2023
CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that
KemPharm: Now A Rare Disease Play, Upgrading To A Buy Rating
10:03am, Friday, 03'rd Feb 2023
We initiated KemPharm with a Sell rating in March 2021; since then, the stock has declined >40%, and now the stock is trading at an attractive enterprise value of $130m. AZSTARYS targeting ADHD has be
KemPharm, Inc. (KMPH) Q3 2022 Earnings Call Transcript
10:01pm, Wednesday, 09'th Nov 2022
KemPharm, Inc. (NASDAQ:KMPH ) Q3 2022 Results Conference Call November 9, 2022 5:00 PM ET Company Participants Nichol Ochsner - Vice President of Investor Relations Travis Mickle - President and Chief
KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th
11:30am, Tuesday, 04'th Oct 2022 GlobeNewswire Inc.
CELEBRATION, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization
KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study
03:42pm, Thursday, 29'th Sep 2022 Zacks Investment Research
KemPharm (KMPH) reports positive top line from a study evaluating serdexmethylphenidate (SDX) for cardiovascular safety to progress the development of its prodrug KP1077.
KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study
12:47pm, Thursday, 29'th Sep 2022
KemPharm (KMPH) reports positive top line from a study evaluating serdexmethylphenidate (SDX) for cardiovascular safety to progress the development of its prodrug KP1077.
US Stocks Turn Lower; Nasdaq Drops Over 100 Points
04:04pm, Thursday, 15'th Sep 2022 Benzinga
U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Thursday.
The Dow traded down 0.12% to 31,099.20 while the NASDAQ fell 1.18% to 11,581.65. T
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2022
02:16pm, Thursday, 15'th Sep 2022 Benzinga
Upgrades
For Nokia Oyj (NYSE:NOK), Credit Suisse upgraded the previous rating of Neutral to Outperform. For the second quarter, Nokia had an EPS of $0.11, compared to year-ago quarter EPS of $0.11. At
KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference
07:30am, Thursday, 01'st Sep 2022
CELEBRATION, Fla., Sept. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commerci
Apple To $220? Here Are 5 Other Price Target Changes For Wednesday
11:15am, Wednesday, 17'th Aug 2022 Benzinga
Wedbush raised the price target on Apple Inc. (NASDAQ: AAPL) from $200 to $220. However, Wedbush analyst Daniel Ives maintained the stock with an Outperform. Apple shares fell 0.2% to $172.69 in pre-
KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates
08:05pm, Thursday, 11'th Aug 2022 GlobeNewswire Inc.
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, August 11, 2022, at 5:00 p.m. ET
KemPharm, Inc. (KMPH) CEO Travis Mickle on Q2 2022 Results - Earnings Call Transcript
07:57pm, Thursday, 11'th Aug 2022
KemPharm, Inc. (NASDAQ:KMPH ) Q2 2022 Earnings Conference Call August 11, 2022 5:00 PM ET Company Participants Nichol Ochsner - Vice President-Investor Relations & Corporate Communications Travis Mick
Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates
09:55pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -72% and 13.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stoc
CTI BioPharma (CTIC) Reports Q2 Loss, Tops Revenue Estimates
10:55pm, Monday, 08'th Aug 2022 Zacks Investment Research
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5% and 20.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Lyell Immunopharma (LYEL) Reports Q2 Loss, Tops Revenue Estimates
10:25pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 51.61% and 960.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?